Quantcast
Skip to main content
Pharmacy

Pharmacy

PGY-2 Cardiology Residency Director

William Dager, Pharm.D., BCPS (AQ-Cardiology)

William.Dager@ucdmc.ucdavis.edu

Current Title(s):

  • Pharmacist Specialist, UC Davis Medical Center
  • Clinical Professor of Medicine, UC Davis School of Medicine
  • Clinical Professor of Pharmacy, Touro University College of Pharmacy

At UC Davis Medical Center since: 1985

Program Director since: 2009

Education:

  • Pharm.D., UC San Francisco School of Pharmacy, 1985
  • General Pharmacy Residency, UC Davis Medical Center, 1986
  • Nephrology Pharmaceutical Care Preceptorship, University of Pittsburgh, 1995

Professional Biography

Bill is a board-certified pharmacotherapy specialist with added qualifications in cardiology. He is aclinical specialist at UC Davis Medical Center, where his practice focus is cardiology, cardiovascular surgery and anticoagulation. He is also involved in pharmacokinetics and management of selected critical care-related situations. He is the director of the PGY-2 residency in cardiology. He currently holds three academic positions, primarily as volunteer faculty.

Bill is a recipient of multiple teaching and mentoring awards, including the ACCP Best Practice award in 2008. He is a reviewer and/or editorial board member for multiple medical journals, including chair of the Editorial Advisory Board panel on anticoagulation for the Annals of Pharmacotherapy. He is also a site coordinator for the ASHP foundation anticoagulation preceptorship.

Bill has authored over 70 peer reviewed articles, over 12 book chapters, and is a co-editor of the ASHP Anticoagulation Therapy POC guide. He is an active lecturer, both nationally and internationally, and has research interests involving anticoagulation, critical care, cardiovascular disease, and pharmacokinetics/pharmacodynamics.

 

Selected Publications

Dager WE, Gulseth MP. Implementing pharmacist anticoagulation management in the inpatient setting. Am J Health-Syst Pharm. 2007;64(10):1071-9.

Janatpour KA, Gosselin RC, Dager WE, Lee A, Owings JT, Wun T. Usefulliness of optical density values from heparin- platelet factor 4 antibody testing and probability scoring models to diagnose heparin induced thrombocytopenia. Am J Clin Path 2007;127:429-33.

Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-Induced Thrombocytopenia: A Review of Treatment Options and Special Considerations. Pharmacotherapy 2007; 27:564-587.

Ellison J, Dager WE. Recent FDA warning on the concomitant use of aspirin and ibuprofen and the effects on platelet aggregation. Preventive Cardiology 2007;10:61-3.

Dager WE. What is the current approach to managing heparin-induced thrombocytopenia? J Crit Illness, 2007:6-8

Dobesh P, Brouse SD, Dager WE, Spinler SA, Stacy Z, Wiggins BS. Key Articles and Guidelines in the Management of Acute Coronary Syndrome and in Percutaneous Coronary Intervention – 2007 Update. Pharmacotherapy 2007;27: 1722-58.

Dager WE. Improving Anticoagulation Management and Continuity of Care for Patients with Atrial Fibrillation. Am J Health-Syst Pharm. 2007;64:2279-2280.

Dager WE. Considerations for drug dosing following Coronary Artery Bypass Graft Surgery (Editorial). The Annals of Pharmacotherapy 2008;42:March 2008

Nutescu E, Splinler S, Wittkowsky, A, Dager W. Low-molecular-weight heparins in renal impairment and obesity: review of available evidence and clinical practice recommendations across medical andsurgical patients. The Annals of Pharmacotherapy 2009;43:1064-83.

Gulseth M, Grice G, Dager W. Pharmacogenomics of Warfarin: Uncovering a piece of the warfarin mystery. Am J Health-Syst Pharm. 2009;66:123-133

Dobesh PP, Wittkowsky AK, Stacy Z, Dager WE, Haines ST, Lopez LM, Nutescu E, Phillips KW, Trujillo TC, Vondracek T. Key articles and guidelines for the prevention of venous thromboembolism. Pharmacotherapy. 2009;29:410-58.

Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. Pharmacotherapy 2009;29:562-77.

Dager WE. Dosing Nomograms: Silos on a slope (Editorial). The Annals of Pharmacotherapy, 2009;43:114-7.

Erstad BL, Brophy GM, Martin SJ, Haas CE, Devlin JW, Welage LS, Dager WE. Key Articles and Guidelines Relative to Intensive Care Unit Pharmacology—2009 Update. Pharmacotherapy 2009;29:1228-1269.

Nishijima DK, Dager WE, Schrot RJ, Holmes JF. The Efficacy of Factor VIIa in Emergency Department Patients with Warfarin Use and Traumatic Intracranial Hemorrhage. Acad Emerg Med. 2010;17:244-51.

Prinzola JL, Smythe MA, Dager WE. Drug Induced Thrombocytopenias in the Critically Ill. Crit Care Med. 2010;38(6 Suppl):S145-54.

Dager WE. Issues inassessing and reducing the risk for venous thromboembolism. Am J Health Syst Pharm. 2010;67(10 Suppl 6):S9-16.

Haines ST, Dager WE, Trujillo TC. Clinical and Management Challenges in Preventing Venous Thromboembolism in Health Systems: A Case-Based Panel Discussion. Am J Health Syst Pharm. 2010;67(10 Suppl 6):S26-30.

Dager WE, Kiser TH.Systemic Anticoagulation Considerations in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2010;17:420-7

Wittkowsky A, Spinler S, Dager W, Gulseth M, Nutescu M. Dosing Guidelines, not protocols, for managing warfarin therapy. Am J Health Syst Pharm. 2010;67:1554-6

Dager WE. Pharmacokinetic and pharmacodynamic concepts with drug regimens in hemodialysis patients. Semin Dial. 2010;23:466-9.

Dager W, Bolstra S,Brophy G, et al. An Opinion Paper Outlining Recommendations for Training, Credentialing, and Documenting and Justifying Critical Care Pharmacy Services. Pharmacotherapy 2011;31:135e-175e Dager WE. Can Enoxaparin be Used Safely in End-Stage Renal Disease? Seminars in Dialysis: 2011;24:381-2

Dager WE. Using prothrombin complex concentrates to rapidly reverse oral anticoagulants. The Annals of Pharmacotherapy, 2011;45:1016-20.

Dager WE, Branch JM: Exploring New Anticoagulants. The RX Script, July/August 2011 Issue

Nagle E, Tsu L, Dager WE. Bivalirudin for Anticoagulation during Hypothermic Cardiopulmonary Bypass and Recombinant Factor VIIa for Iatrogenic Coagulopathy. The Annals of Pharmacotherapy 2011;45:e47

Stacy ZA, Dobesh PP, Trujillo TC, Dager WE, Olson KL. Key Articles and Guidelines in the Management of Peripheral Arterial Disease. Pharmacotherapy 2011;31:922

Tsu L, Dager WE. Bivalirudin dosing patterns for renal function including presence of hemodialysis in the management of heparin induced thrombocytopenia. The Annals of Pharmacotherapy 2011;45:1185-92

Gosselin RC, Dager WE, Roberts AJ et al. Effect of telavancin (VIBATIV) on routine coagulation testing. Am J Clin Path 2011;136:848-54

Heintz BH, Thompson III GR, Dager WE. Clinical Experience with Aminoglycosides in Dialysis-Dependent Patients: Risk Factors for Mortality and Reassessment of Current Dosing Practices. The Annals of Pharmacotherapy 2011; 45:1338-45

Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA. Use of Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness. Pharmacotherapy 2011;31:1232-49

Tsu L, Dager WE. Comparison of Bivalirudin Dosing Using Total, Adjusted, or Ideal Body Weights in Obese Patients with Heparin-Induced Thrombocytopenia. Pharmacotherapy 2012;32:

Dager WE. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty:exploring the evidence, guidelines and challenges remaining. The Annals of Pharmacotherapy 2012;46:79-88